Combining radiotherapy and angiogenesis inhibitors: Clinical trial design

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 1, 2006, Pages 15-25

  Citrin, Deborah ^a   Ménard, Cynthia ^b   Camphausen, Kevin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Angiogenesis; Angiogenesis inhibitor; Antiangiogenic therapy; Radiotherapy

Indexed keywords

ANGIOGRAPHY; CHEMOTHERAPY; CLINICAL LABORATORIES; DRUG DOSAGE; RADIOTHERAPY;

ANGIOGENESIS; ANGIOGENESIS INHIBITOR; ANTIANGIOGENIC THERAPY;

ONCOLOGY;

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOSTATIN; BEVACIZUMAB; CYTOKINE; GROWTH FACTOR; MONOCLONAL ANTIBODY DC101; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; GENE MUTATION; HUMAN; IMAGING; LABORATORY; MICROENVIRONMENT; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; TREATMENT OUTCOME; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CLINICAL PROTOCOLS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATIENT SELECTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 29244453204     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.03.065     Document Type: Conference Paper

References (127)

1. D.H. Ausprunk, J. Folkman Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis Microvasc Res 14 1977 53 65
2. J. Folkman How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture Cancer Res 46 1986 467 473
3. P. Hahnfeldt, D. Panigrahy, J. Folkman Tumor development under angiogenic signaling A dynamical theory of tumor growth, treatment response, and postvascular dormancy Cancer Res 59 1999 4770 4775
4. H. Hashizume, P. Baluk, S. Morikawa Openings between defective endothelial cells explain tumor vessel leakiness Am J Pathol 156 2000 1363 1380
5. S. Morikawa, P. Baluk, T. Kaidoh Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors Am J Pathol 160 2002 985 1000
6. R.K. Jain, L.L. Munn, D. Fukumura Dissecting tumour pathophysiology using intravital microscopy Nat Rev Cancer 2 2002 266 276
7. R.K. Jain Determinants of tumor blood flow A review Cancer Res 48 1988 2641 2658
8. I. Tufto, E.K. Rofstad Transient perfusion in human melanoma xenografts Br J Cancer 71 1995 789 793
9. R.E. Durand, N.E. LePard Contribution of transient blood flow to tumour hypoxia in mice Acta Oncol 34 1995 317 323
10. D.J. Chaplin, P.L. Olive, R.E. Durand Intermittent blood flow in a murine tumor radiobiological effects Cancer Res 47 1987 597 601
11. D.J. Chaplin, R.E. Durand, P.L. Olive Acute hypoxia in tumors Implications for modifiers of radiation effects Int J Radiat Oncol Biol Phys 12 1986 1279 1282
12. J. Bussink, J.H. Kaanders, A.J. van der Kogel Tumor hypoxia at the micro-regional level Clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers Radiother Oncol 67 2003 3 15
13. E. Hall Radiobiology for the radiologist 5th ed. 2000 Lippincott, Williams & Wilkins Philadelphia
14. B.A. Teicher, S.A. Holden, G. Ara Influence of an anti-angiogenic treatment on 9L gliosarcoma Oxygenation and response to cytotoxic therapy Int J Cancer 61 1995 732 737
15. C.G. Lee, M. Heijn, E. di Tomaso Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 60 2000 5565 5570
16. R.J. Griffin, B.W. Williams, R. Wild Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response Cancer Res 62 2002 1702 1706
17. B.A. Teicher, S.A. Holden, G. Ara Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents Int J Cancer 57 1994 920 925
18. P. Wachsberger, R. Burd, A.P. Dicker Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents Exploring mechanisms of interaction Clin Cancer Res 9 2003 1957 1971
19. M.S. O'Reilly, L. Holmgren, C. Chen Angiostatin induces and sustains dormancy of human primary tumors in mice Nat Med 2 1996 689 692
20. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy A new paradigm for combination therapy Nat Med 7 2001 987 989
21. R.T. Tong, Y. Boucher, S.V. Kozin Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 2004 3731 3736
22. F. Yuan, Y. Chen, M. Dellian Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody Proc Natl Acad Sci USA 93 1996 14765 14770
23. J. Folkman, K. Camphausen Cancer What does radiotherapy do to endothelial cells? Science 293 2001 227 228
24. D.H. Gorski, M.A. Beckett, N.T. Jaskowiak Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378
25. L. Geng, E. Donnelly, G. McMahon Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy Cancer Res 61 2001 2413 2419
26. R.M. Shaheen, W.W. Tseng, D.W. Davis Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms Cancer Res 61 2001 1464 1468
27. C. Ruegg, J.Y. Meuwly, R. Driscoll The quest for surrogate markers of angiogenesis A paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials Curr Mol Med 3 2003 673 691
28. T. Boehm, J. Folkman, T. Browder Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 1997 404 407
29. J. Drevs, C. Laus, M. Mendinger Antiangiogenesis Current clinical data and future perspectives Onkologie 25 2002 520 527
30. R.S. Kerbel, J. Yu, J. Tran Possible mechanisms of acquired resistance to anti-angiogenic drugs Implications for the use of combination therapy approaches Cancer Metast Rev 20 2001 79 86
31. J.L. Yu, J.W. Rak, B.L. Coomber Effect of p53 status on tumor response to antiangiogenic therapy Science 295 2002 1526 1528
32. D.E. Richard, E. Berra, J. Pouyssegur Angiogenesis How a tumor adapts to hypoxia Biochem Biophys Res Commun 266 1999 718 722
33. M.I. Koukourakis, A. Giatromanolaki, E. Sivridis Squamous cell head and neck cancer Evidence of angiogenic regeneration during radiotherapy Anticancer Res 21 2001 4301 4309
34. O. Katoh, H. Tauchi, K. Kawaishi Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation Cancer Res 55 1995 5687 5692
35. V.K. Gupta, N.T. Jaskowiak, M.A. Beckett Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance Cancer J 8 2002 47 54
36. P. Kumar, A.I. Miller, P.J. Polverini p38 MAPK mediates γ-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway J Biol Chem 279 2004 43352 43360
37. B.D. Smith, G.L. Smith, D. Carter Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma J Clin Oncol 18 2000 2046 2052
38. B. Linderholm, K. Grankvist, N. Wilking Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment J Clin Oncol 18 2000 1423 1431
39. J.K. Jameel, V.S. Rao, L. Cawkwell Radioresistance in carcinoma of the breast Breast 13 2004 452 460
40. J.O. Kang, S.E. Hong The prognostic effect of VEGF expression in squamous cell carcinoma of the cervix treated with radiation therapy alone J Korean Med Sci 19 2004 693 697
41. D.H. Nam, K. Park, Y.L. Suh Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma Prognostic significance Oncol Rep 11 2004 863 869
42. J. Folkman, D. Ingber Inhibition of angiogenesis Semin Cancer Biol 3 1992 89 96
43. I.F. Tannock Tumor physiology and drug resistance Cancer Metast Rev 20 2001 123 132
44. B.C. Kuenen, L. Rosen, E.F. Smit Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors J Clin Oncol 20 2002 1657 1667
45. G.M. Marx, C.B. Steer, P. Harper Unexpected serious toxicity with chemotherapy and antiangiogenic combinations Time to take stock! J Clin Oncol 20 2002 1446 1448
46. W.U. Shipley, J.A. Stanley, G.G. Steel Tumor size dependency in the radiation response of the Lewis lung carcinoma Cancer Res 35 1975 2488 2493
47. G. Bergers, K. Javaherian, K.M. Lo Effects of angiogenesis inhibitors on multistage carcinogenesis in mice Science 284 1999 808 812
48. J. Folkman Angiogenesis-dependent diseases Semin Oncol 28 2001 536 542
49. J. Folkman Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 2002 15 18
50. P. Carmeliet, R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
51. U. Cavallaro, G. Christofori Molecular mechanisms of tumor angiogenesis and tumor progression J Neurooncol 50 2000 63 70
52. B.A. Teicher, E.A. Sotomayor, Z.D. Huang Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease Cancer Res 52 1992 6702 6704
53. W.L. Dahut, J.L. Gulley, P.M. Arlen Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer J Clin Oncol 22 2004 2532 2539
54. F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
55. J.V. Heymach, J. Desai, J. Manola Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas Clin Cancer Res 10 2004 5732 5740
56. G. Deplanque, S. Madhusudan, P.H. Jones Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma Br J Cancer 91 2004 1645 1650
57. A.C. Peterson, S. Swiger, W.M. Stadler Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma Clin Cancer Res 10 2004 4048 4054
58. W.M. Stadler, D. Cao, N.J. Vogelzang A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer Clin Cancer Res 10 2004 3365 3370
59. Y. Cao, M.S. O'Reilly, B. Marshall Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases J Clin Invest 101 1998 1055 1063
60. L. Holmgren, M.S. O'Reilly, J. Folkman Dormancy of micrometastases Balanced proliferation and apoptosis in the presence of angiogenesis suppression Nat Med 1 1995 149 153
61. M.S. O'Reilly, L. Holmgren, Y. Shing Angiostatin A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma Cell 79 1994 315 328
62. A. Yamamoto, S. Yano, M. Shiraga A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice Int J Cancer 103 2003 822 828
63. H.J. Mauceri, S. Seetharam, M.A. Beckett Angiostatin potentiates cyclophosphamide treatment of metastatic disease Cancer Chemother Pharmacol 50 2002 412 418
64. K.S. Klos, X. Zhou, S. Lee Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone Cancer 98 2003 1377 1385
65. S. Ning, D. Laird, J.M. Cherrington The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation Radiat Res 157 2002 45 51
66. C. Hess, V. Vuong, I. Hegyi Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth Br J Cancer 85 2001 2010 2016
67. J. Dancey, E.A. Sausville Issues and progress with protein kinase inhibitors for cancer treatment Nat Rev Drug Discov 2 2003 296 313
68. E.K. Rowinsky Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies J Clin Oncol 21 2003 175 186
69. R.S. Kerbel, B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nat Rev Cancer 4 2004 423 436
70. G. Gasparini Metronomic scheduling The future of chemotherapy? Lancet Oncol 2 2001 733 740
71. T. Browder, C.E. Butterfield, B.M. Kraling Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 2000 1878 1886
72. F.M. Sirotnak, M.F. Zakowski, V.A. Miller Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase Clin Cancer Res 6 2000 4885 4892
73. L. Bello, G. Carrabba, C. Giussani Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo Cancer Res 61 2001 7501 7506
74. O. Kisker, C.M. Becker, D. Prox Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model Cancer Res 61 2001 7669 7674
75. G. Petrangolini, G. Pratesi, M. De Cesare Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts Mol Cancer Res 1 2003 863 870
76. A. Ergun, K. Camphausen, L.M. Wein Optimal scheduling of radiotherapy and angiogenic inhibitors Bull Math Biol 65 2003 407 424
77. D.E. Hilmas, E.L. Gillette Tumor microvasculature following fractionated X irradiation Radiology 116 1975 165 169
78. M.M. Cooney, K.-Y. Tserng, V. Makar A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck Cancer Chemother Pharmacol 55 2005 295 300
79. C.-K. Lee, B. Barlogie, N. Munshi DTPACE An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma J Clin Oncol 21 2003 2732 2739
80. M. Jansen, P.C. de Witt Hamer, A.N. Witmer Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas Brain Res Brain Res Rev 45 2004 143 163
81. P.A. Burke, S.J. DeNardo Antiangiogenic agents and their promising potential in combined therapy Crit Rev Oncol Hematol 39 2001 155 171
82. H.J. Bernsen, P.F. Rijken, T. Oostendorp Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse Br J Cancer 71 1995 721 726
83. K. Takada, S. Yamada, A. Teramoto Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas Endocrin Pathol 15 2004 131 139
84. G. Tan, A.M. Cioc, D. Perez-Montiel Microvascular density does not correlate with histopathology and outcome in neuroendocrine tumors of the pancreas Appl Immunohistochem Mol Morphol 12 2004 31 35
85. U. Coskun, N. Gunel, B. Sancak Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients Breast 12 2003 104 110
86. G. Sliutz, C. Tempfer, A. Obermair Serum evaluation of basic FGF in breast cancer patients Anticancer Res 15 1995 2675 2677
87. R.T. Poon, J.W. Ho, C.S. Tong Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma Br J Surg 91 2004 1354 1360
88. M. Tamura, M. Oda, I. Matsumoto The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer Ann Surg Oncol 11 2004 928 933
89. M. Tamura, M. Oda, Y. Tsunezuka Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer Chest 126 2004 342 346
90. L. Li, L. Wang, W. Zhang Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer Anticancer Res 24 2004 1973 1979
91. A. Alvarez Secord, R. Sayer, S.A. Snyder The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer Gynecol Oncol 94 2004 74 79
92. A. Kaya, A. Ciledag, B.E. Gulbay The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients Respir Med 98 2004 632 636
93. J.P. Braybrooke, K.J. O'Byrne, D.J. Propper A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis Clin Cancer Res 6 2000 4697 4704
94. H.A. Fine, W.D. Figg, K. Jaeckle Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas J Clin Oncol 18 2000 708 715
95. H. Shimada, A. Takeda, Y. Nabeya Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma Cancer 92 2001 663 669
96. J.H. Choi, M.J. Ahn, S.J. Jang Absence of clinical prognostic value of vascular endothelial growth factor and microvessel density in multiple myeloma Int J Hematol 76 2002 460 464
97. S.H. Park, S.S. Lee The relationship between serum VEGF concentration and prognosis of lung cancer Korean J Intern Med 18 2003 207 211
98. S. Negrier, D. Perol, C. Menetrier-Caux Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma Prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie J Clin Oncol 22 2004 2371 2378
99. C. Ribas, G.W. Colleoni, M.R. Silva Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma Eur J Haematol 73 2004 311 317
100. C. Nieder, N. Andratschke, B. Jeremic Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer Anticancer Res 23 2003 5117 5123
101. L.W. Chan, M.A. Moses, E. Goley Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy A longitudinal study of protein kinetics throughout tumor progression and therapy J Clin Oncol 22 2004 499 506
102. R. Ria, M. Portaluri, F. Russo Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy Cancer Lett 216 2004 103 107
103. H. Shimada, T. Hoshino, S. Okazumi Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma Br J Cancer 86 2002 552 557
104. H. Kumar, K. Heer, J. Greenman Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients Anticancer Res 22 2002 1877 1880
105. M. Bewick, M. Conlon, H. Lee Evaluation of sICAM-1, sVCAM-1, and sE-selectin levels in patients with metastatic breast cancer receiving high-dose chemotherapy Stem Cells Dev 13 2004 281 294
106. T. Opala, K. Drews, P. Rzymski Evaluation of soluble intracellular adhesion molecule-1 (sICAM-1) in benign and malignant ovarian masses Eur J Gynaecol Oncol 24 2003 255 257
107. Z. Pasieka, H. Stepien, J. Komorowski Evaluation of the levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in serum of patients with thyroid cancer Recent Results Cancer Res 162 2003 189 194
108. M.S. Boulbou, G.N. Koukoulis, E.D. Makri Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension Int J Cardiol 98 2005 39 44
109. W. Marz, H. Scharnagl, K. Winkler Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease The Ludwigshafen Risk and Cardiovascular Health study Circulation 110 2004 3068 3074
110. J. Mocco, T.F. Choudhri, W.J. Mack Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis Neurosurgery 48 2001 718 721
111. A.J. Littler, C.D. Buckley, P. Wordsworth A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis Br J Rheumatol 36 1997 164 169
112. J.J. Cush, R. Rothlein, H.B. Lindsley Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis Arthritis Rheum 36 1993 1098 1102
113. H. Ihn, M. Fujimoto, S. Sato Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma J Am Acad Dermatol 31 1994 591 595
114. R.A. Nordal, C.S. Wong Intercellular adhesion molecule-1 and blood-spinal cord barrier disruption in central nervous system radiation injury J Neuropathol Exp Neurol 63 2004 474 483
115. Y. Ishii, S. Kitamura Soluble intercellular adhesion molecule-1 as an early detection marker for radiation pneumonitis Eur Respir J 13 1999 733 738
116. A.M. Davidoff, C.Y.C. Ng, P. Brown Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice Clin Cancer Res 7 2001 2870 2879
117. D. Lyden, K. Hattori, S. Dias Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth Nat Med 7 2001 1194 1201
118. M. Capillo, P. Mancuso, A. Gobbi Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors Clin Cancer Res 9 2003 377 382
119. S. Shintani, T. Murohara, H. Ikeda Mobilization of endothelial progenitor cells in patients with acute myocardial infarction Circulation 103 2001 2776 2779
120. M. Gill, S. Dias, K. Hattori Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells Circ Res 88 2001 167 174
121. C. Rabascio, E. Muratori, P. Mancuso Assessing tumor angiogenesis Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells Cancer Res 64 2004 4373 4377
122. D. Cosgrove Angiogenesis imaging - Ultrasound Br J Radiol 76 2003 S43 S49
123. F. Forsberg, R. Ro, M. Potoczek Assessment of angiogenesis implications for ultrasound imaging Ultrasonics 42 2004 325 330
124. M. Kothari, A. Guermazi, D. White Imaging in antiangiogenesis trial A clinical trials radiology perspective Br J Radiol 76 2003 S92 S96
125. M. Schirner, A. Menrad, A. Stephens Molecular imaging of tumor angiogenesis Ann NY Acad Sci 1014 2004 67 75
126. A. Padhani Dynamic contrast-enhanced MRI in clinical oncology Current status and future directions J Magn Reson Imaging 16 2002 407 422
127. P. Choyke, A. Dwyer, M. Knopp Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging J Magn Reson Imaging 17 2003 509 520